Clinical Trial Update: TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options. [Phase 3]

View source ↗

Summary

A Phase III study (TMC125-C206) evaluated etravirine (TMC125) as part of an antiretroviral regimen with darunavir/ritonavir and an investigator-selected backgro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Ritonavir (Ritonavir)
• TMC114 (darunavir)
• TMC125 (dapivirine)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV | Phase 3 | Status: COMPLETED